安进抗FGFR2b单抗在一线胃癌治疗后期试验中取得积极成果

药事纵横2025-07-03

自安进公司斥资近20亿美元收购Five Prime公司及其针对FGFR2b的单克隆抗体（mAb）以来，已过去四年多。如今，贝马妥珠单抗（bemarituzumab）的新数据证明了安进公司这一决策的正确性。6月30日，安进公司公布了一项胃癌III期临床试验的主要结果，显示该单克隆抗体达到了主要生存终点。尽管这家制药公司未透露此次临床试验成功的具体细节，但承诺会在未来的医学会议上提供详细数据。这项名为...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2548434498?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2025-07-03 06:03","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2548434498","market":"us","top_or_hot":-1,"title":"安进抗FGFR2b单抗在一线胃癌治疗后期试验中取得积极成果","media":"药事纵横","content":"<div>\n<p>自安进公司斥资近20亿美元收购Five Prime公司及其针对FGFR2b的单克隆抗体（mAb）以来，已过去四年多。如今，贝马妥珠单抗（bemarituzumab）的新数据证明了安进公司这一决策的正确性。6月30日，安进公司公布了一项胃癌III期临床试验的主要结果，显示该单克隆抗体达到了主要生存终点。尽管这家制药公司未透露此次临床试验成功的具体细节，但承诺会在未来的医学会议上提供详细数据。这项名为...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250703060541a72b3f1c&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>安进抗FGFR2b单抗在一线胃癌治疗后期试验中取得积极成果</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n安进抗FGFR2b单抗在一线胃癌治疗后期试验中取得积极成果\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-07-03 06:03 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250703060541a72b3f1c&s=b><strong>药事纵横</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>自安进公司斥资近20亿美元收购Five Prime公司及其针对FGFR2b的单克隆抗体（mAb）以来，已过去四年多。如今，贝马妥珠单抗（bemarituzumab）的新数据证明了安进公司这一决策的正确性。6月30日，安进公司公布了一项胃癌III期临床试验的主要结果，显示该单克隆抗体达到了主要生存终点。尽管这家制药公司未透露此次临床试验成功的具体细节，但承诺会在未来的医学会议上提供详细数据。这项名为...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250703060541a72b3f1c&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0868494617.USD","symbol_name":"UBS (LUX) EQUITY SICAV - US TOTAL YIELD SUSTAINABLE \"P\" (USD) ACC","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250703060541a72b3f1c&s=b","article_id":"2548434498","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250703060541a72b3f1c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2548434498","pubTimestamp":1751493795,"columns":[],"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"自安进公司斥资近20亿美元收购Five Prime公司及其针对FGFR2b的单克隆抗体以来，已过去四年多。6月30日，安进公司公布了一项胃癌III期临床试验的主要结果，显示该单克隆抗体达到了主要生存终点。此外，34.2%接受贝马妥珠单抗治疗的患者因不良事件而中断治疗，而安慰剂组仅为5.2%。此外，双方合作伙伴还在开展一项贝马妥珠单抗联合化疗及百时美施贵宝公司的纳武利尤单抗作为胃癌一线治疗的III期试验，预计今年下半年公布数据。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"LU0868494617.USD":"UBS (LUX) EQUITY SICAV - US TOTAL YIELD SUSTAINABLE \"P\" (USD) ACC","LU0109394709.USD":"富兰克林生物科技新领域基金A (acc)","LU0122379950.USD":"贝莱德世界健康科学A2","LU1983299246.USD":"SCHRODER ISF HEALTHCARE INNOVATION \"A\" (USD) ACC","BK4581":"高盛持仓","BK4599":"减肥药","LU0058720904.USD":"联博国际健康护理基金A","LU2242646821.SGD":"Fidelity Global Dividend Plus A-MINCOME(G)-SGD","IE0009355771.USD":"骏利亨德森环球生命科技A Acc","SG9999001440.SGD":"United Global Dividend Equity Fund A SGD Dist","LU2468319806.SGD":"MANULIFE GF HEALTHCARE \"AA\" (SGDHDG) ACC","BK4534":"瑞士信贷持仓","BK4585":"ETF&股票定投概念","LU0289739699.SGD":"AB INTERNATIONAL HEALTH CARE PORTFOLIO \"A\" (SGD) ACC","BK4139":"生物科技","LU1057294990.SGD":"Blackrock World Healthscience A2 SGD-H","LU2242652126.USD":"FIDELITY FUNDS GLOBAL DIVIDENDS PLUS \"A\" (USD) INC","LU1571399168.USD":"ALLSPRING GLOBAL LONG/SHORT EQUITY \"IP\" (USD) ACC","LU0889565916.HKD":"FRANKLIN BIOTECHNOLOGY DISCOVERY \"A\" (HKD) ACC","IE00B2B36J28.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I1\" (USD) INC","BK4533":"AQR资本管理(全球第二大对冲基金)","IE00BJT1NW94.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (SGDHDG) ACC","BK4566":"资本集团","LU2089984988.USD":"MANULIFE GF HEALTHCARE \"AA\" (USD) ACC","LU2112291526.USD":"BGF WORLD HEALTHSCIENCE \"A4\" (USD) INC","IE0002141913.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (USD) ACC","LU1023059063.AUD":"BGF WORLD HEALTHSCIENCE \"A2\" (AUDHDG) ACC","IE00BJJMRZ35.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (SGDHDG) ACC","BK4588":"碎股","IE00BFTCPJ56.SGD":"Janus Henderson Global Life Sciences A Acc SGD","LU1061106388.HKD":"BGF WORLD HEALTHSCIENCE \"A2\" (HKDHDG) ACC","AMGN":"安进","LU0320765992.SGD":"FTIF - Franklin Biotechnology Discovery A Acc SGD","IE00B4R5TH58.HKD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (HKD) ACC"},"translate_title":"Amgen's anti-FGFR2b monoclonal antibody achieves positive results in late-stage trial for first-line gastric cancer treatment","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AMGN":1},"content_text":"自安进公司斥资近20亿美元收购Five Prime公司及其针对FGFR2b的单克隆抗体（mAb）以来，已过去四年多。如今，贝马妥珠单抗（bemarituzumab）的新数据证明了安进公司这一决策的正确性。6月30日，安进公司公布了一项胃癌III期临床试验的主要结果，显示该单克隆抗体达到了主要生存终点。尽管这家制药公司未透露此次临床试验成功的具体细节，但承诺会在未来的医学会议上提供详细数据。这项名为FORTITUDE-101的III期临床试验共招募了547名患有不可切除、局部晚期或转移性非HER2阳性、FGFR2b过表达的胃癌或胃食管交界处（GEJ）癌的患者。参与者被随机分组，一组接受一线贝马妥珠单抗联合化疗（mFOLFOX6方案）治疗，另一组仅接受化疗。根据预先设定的中期分析结果，联合治疗组在总生存期（OS）方面相比单纯化疗组，取得了具有统计学意义和临床意义的显著改善，达到了试验的主要终点。安进公司负责研发的执行副总裁杰伊·布拉德纳（Jay Bradner）表示：“大多数胃癌患者在确诊时已处于晚期，预后较差，生存率低，且治疗选择有限。”他补充道，此次研究结果“标志着在开发有效胃癌靶向治疗药物方面取得了具有重大意义的进展”。此次结果也印证了II期临床试验的发现。在II期试验中，贝马妥珠单抗联合化疗相较于单纯化疗，显著延长了患者的无进展生存期和总生存期。II期试验也显示，接受贝马妥珠单抗治疗的患者角膜和口腔炎等不良事件（AEs）的发生率更高。实验药物组中至少出现3级不良事件的患者比例达82.9%，而安慰剂组为74%。此外，34.2%接受贝马妥珠单抗治疗的患者因不良事件而中断治疗，而安慰剂组仅为5.2%。在III期试验中，贝马妥珠单抗组眼部不良事件的发生“频率更高，严重程度也更高”。超过四分之一接受该单克隆抗体治疗的患者出现了视力下降、点状角膜炎、贫血、中性粒细胞减少、恶心、角膜上皮缺损或干眼等症状。FORTITUDE-101试验得到了再鼎医药的支持。2017年，再鼎医药从Five Prime公司独家获得了贝马妥珠单抗在中国大陆、香港、澳门和台湾地区的共同开发与商业化权利。此外，双方合作伙伴还在开展一项贝马妥珠单抗联合化疗及百时美施贵宝公司的纳武利尤单抗（Opdivo，商品名）作为胃癌一线治疗的III期试验，预计今年下半年公布数据。药事纵横投稿须知：稿费已上调，欢迎投稿","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2548434498","isCrawlerRequest":true}